Goodrx Holdings, INC 10-Q quarterly reports

GoodRx Holdings reports a decrease in revenue and net income for Q1 2026, impacted by retail pharmacy landscape changes and a shift towards Pharma Direct offerings.

GoodRx reported a slight revenue increase but a significant net income drop in Q3 2025, as growth in pharma solutions was offset by declines in prescription transactions and active consumers amid retail pharmacy landscape changes.

GoodRx reports increased net income and Adjusted EBITDA in Q2 2025, despite declines in prescription transactions and subscription revenue due to retail pharmacy landscape changes.

GoodRx Holdings, Inc. reports a 3% increase in revenue and a return to net income profitability for the first quarter of 2025, navigating changes in the retail pharmacy sector.

GoodRx Holdings saw an 8% increase in revenue and a significant improvement in profitability in the third quarter of 2024, compared to the same period last year.

GoodRx Holdings, Inc. announced a 6% increase in revenue for the second quarter of 2024, alongside a decrease in net income compared to the same period last year, while navigating a changing retail pharmacy environment.

GoodRx Holdings saw an 8% increase in revenue in the first quarter of 2024, driven by growth in prescription transactions and pharma manufacturer solutions, while navigating strategic changes.